In-stent restenosis treatment with seal-wing paclitaxel-eluting
balloon catheters

J 2021

In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters

PLEVA, Leos, Pavel KUKLA, Jana ZAPLETALOVA a Ota HLINOMAZ

Základní údaje

Originální název

In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters

Autoři

PLEVA, Leos (203 Česká republika, garant), Pavel KUKLA (203 Česká republika), Jana ZAPLETALOVA (203 Česká republika) a Ota HLINOMAZ (203 Česká republika, domácí)

Vydání

cor et Vasa, AMSTERDAM, ELSEVIER SCIENCE BV, 2021, 0010-8650

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Kód RIV

RIV/00216224:14110/21:00124158

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.33678/cor.2021.013

UT WoS

000694709000003

Klíčová slova anglicky

In-stent restenosis; Paclitaxel-eluting balloon; Seal-wing PEB

Štítky

14110115, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 2. 2022 10:53, Mgr. Tereza Miškechová

Anotace

V originále

Objectives: We aimed to compare the long-term clinical outcomes of seal-wing and iopromide-coated pacli-taxel eluting balloon catheters (PEB) in the treatment of bare-metal stent restenosis (BMS-ISR). Methods: A 3-year clinical follow-up of 132 patients with BMS-ISR was performed, of whom 64 were treated with seal-wing PEB; the control group consisted of 68 patients from iopromide-coated PEB branch of the previous TIS study. The primary endpoint was the occurrence of major adverse cardiac events (MACE; cardio-vascular [CV] death, myocardial infarction [MI], or target vessel revascularization [TVR]). Results: Compared to iopromide-coated PEB, the incidence of 3-year MACE was significantly higher (40.6% vs. 19.1%; p = 0.008) in the seal-wing PEB group; a similar difference was achieved when comparing the need for TVR (26.9% vs. 8.8%; p = 0.011). The event-free survival in the iopromide-coated PEB group was signifi-cantly longer (p = 0.021). There were no differences in cardiovascular mortality (4.7% vs. 5.9%; p = 1.000), occurrence of MI (6.3% vs. 4.4%; p = 0.712), definite ST (0% vs. 2.9%; p = 0.497) or repeated MACE (4.7% vs. 1.5%; p = 0.354) between the two groups. Conclusion: Compared to iopromide-coated PEB, the use of seal-wing PEB in the treatment of BMS-ISR is as-sociated with a significantly higher 3-year incidence of MACE and TVR

Citovat

PLEVA, Leos, Pavel KUKLA, Jana ZAPLETALOVA a Ota HLINOMAZ. In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters. cor et Vasa. AMSTERDAM: ELSEVIER SCIENCE BV, 2021, roč. 63, č. 4, s. 442-447. ISSN 0010-8650. Dostupné z: https://dx.doi.org/10.33678/cor.2021.013.

@article{1834325,
   author = {Pleva, Leos and Kukla, Pavel and Zapletalova, Jana and Hlinomaz, Ota},
   article_location = {AMSTERDAM},
   article_number = {4},
   doi = {http://dx.doi.org/10.33678/cor.2021.013},
   keywords = {In-stent restenosis; Paclitaxel-eluting balloon; Seal-wing PEB},
   language = {eng},
   issn = {0010-8650},
   journal = {cor et Vasa},
   title = {In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters},
   url = {https://e-coretvasa.cz/artkey/cor-202104-0003_in-stent-restenosis-treatment-with-seal-wing-paclitaxel-eluting-balloon-catheters.php},
   volume = {63},
   year = {2021}
}

TY  - JOUR
ID  - 1834325
AU  - Pleva, Leos - Kukla, Pavel - Zapletalova, Jana - Hlinomaz, Ota
PY  - 2021
TI  - In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters
JF  - cor et Vasa
VL  - 63
IS  - 4
SP  - 442-447
EP  - 442-447
PB  - ELSEVIER SCIENCE BV
SN  - 00108650
KW  - In-stent restenosis
KW  - Paclitaxel-eluting balloon
KW  - Seal-wing PEB
UR  - https://e-coretvasa.cz/artkey/cor-202104-0003_in-stent-restenosis-treatment-with-seal-wing-paclitaxel-eluting-balloon-catheters.php
N2  - Objectives: We aimed to compare the long-term clinical outcomes of seal-wing and iopromide-coated pacli-taxel eluting balloon catheters (PEB) in the treatment of bare-metal stent restenosis (BMS-ISR). Methods: A 3-year clinical follow-up of 132 patients with BMS-ISR was performed, of whom 64 were treated with seal-wing PEB; the control group consisted of 68 patients from iopromide-coated PEB branch of the previous TIS study. The primary endpoint was the occurrence of major adverse cardiac events (MACE; cardio-vascular [CV] death, myocardial infarction [MI], or target vessel revascularization [TVR]). Results: Compared to iopromide-coated PEB, the incidence of 3-year MACE was significantly higher (40.6% vs. 19.1%; p = 0.008) in the seal-wing PEB group; a similar difference was achieved when comparing the need for TVR (26.9% vs. 8.8%; p = 0.011). The event-free survival in the iopromide-coated PEB group was signifi-cantly longer (p = 0.021). There were no differences in cardiovascular mortality (4.7% vs. 5.9%; p = 1.000), occurrence of MI (6.3% vs. 4.4%; p = 0.712), definite ST (0% vs. 2.9%; p = 0.497) or repeated MACE (4.7% vs. 1.5%; p = 0.354) between the two groups. Conclusion: Compared to iopromide-coated PEB, the use of seal-wing PEB in the treatment of BMS-ISR is as-sociated with a significantly higher 3-year incidence of MACE and TVR
ER  -

PLEVA, Leos, Pavel KUKLA, Jana ZAPLETALOVA a Ota HLINOMAZ. In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters. \textit{cor et Vasa}. AMSTERDAM: ELSEVIER SCIENCE BV, 2021, roč.~63, č.~4, s.~442-447. ISSN~0010-8650. Dostupné z: https://dx.doi.org/10.33678/cor.2021.013.

Podrobný výpis o publikaci